再次肿瘤组织活检对复发性肺癌精准治疗的重要意义探索性研究

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:xueyingnn
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  目的:近年来针对肿瘤内部异质性的探索成为了新的研究热点。大多数肺癌在最初阶段对治疗一定程度的有效反应。经过一段时期后,残留的癌细胞亚群可致肿瘤复发或者转移。复发瘤的癌细胞遗传不稳定性增强,给临床治疗带来不小的障碍。
其他文献
Objective: To explore the risk factors of brain metastasis (BM) and the role of treatment in patients with small cell lung cancer.Method: Clinical data of 263 prophylactic cranial irradiation (PCI) na
目的:血管生成是乳腺癌转移的关键步骤。肿瘤相关巨噬细胞(Tumor-associated macrophages,TAMs)是肿瘤炎症微环境中主要细胞成分,能够促血管生成及肿瘤转移。本研究拟探讨乳腺癌组织中TAM浸润水平与血管生成及预后的相关性。
Objective: KRAS mutation was a poor prognostic factor in NSCLC, the patients with KRAS-MT has shorter survival than those of KRAS-WT.So it is urgentto further investigate the role of KRAS pathway and
Objective: The aim of this study is to investigate the correlation of histopathologic subtypes with epidermal growth factor receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in lung ad
Objective: The effects of antituberculosis treatment in patients with coexistence of lung cancer and pulmonary tuberculosis has not been known well.The aim of this study was to investigate the curativ
Objective: Hsa-miRNA-206 (miR-206), highly expressed inskeletal muscle, has recently been discovered to have anticancer properties indifferent tissues.However, the role of miR-206 on lung cancer is st
目的:讨论颅内室管膜瘤的临床特点和治疗转归。方法:回顾性分析2009年1月~2012年6月收治的经病理证实的30例颅内室管膜瘤术后放射治疗患者的临床资料,观察疗效并结合文献进行分析。
Objective: MicroRNA plays a crucial role in development and progression of multiple malignancies.However, the mechanisms of microRNA in cancer are not totally clear.
Objective: To evaluate the clinical activity of angiogenesis inhibitor Endostar (rh-endostatin) in combination with continued EGFR-TKIs (including erlotinib, gefitinib and IcotinibO) for advanced NSCL
Objective: To evaluate the efficacy of treatment with dose-escalated icotinib after resistance to routine dose of icotinib for the patients of the advanced non-smoll cell lung cancer.